Project Grant HT94252510051
Award Date
6/1/25
Completion Date
5/31/29
Dollars Obligated
$3.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Allegheny-West, PA 15212, USA
Similar Awards
This $2,165,991 Project Grant was awarded by the Department of Defense (DoD) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will fund the Allegheny Singer Research Institute (AHN Research Institute) to conduct research on "FAST TILS TO TREAT METASTATIC CANCER PATIENTS WITH PLEURAL DISEASE." The research aims to explore T-Cell Infused Lymphocyte Therapy as an innovative approach to treating metastatic cancer. The grant period runs from...
This federal Project Grant award from the Defense Health Agency supports research at the University of Pittsburgh to investigate the effects of intracavitary conditioning in breast cancer metastatic to the pleura or peritoneum. The $4,902,315 award, provided under the Military Medical Research and Development (CFDA 12.420) program, will fund this research work from June 1, 2025 through May 31, 2029. The University of Pittsburgh, a major public research university, will conduct sophisticated...
The University of Pittsburgh was awarded a $925,680 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2027 targeting the IGFBP2-SRC signaling axis to block metastatic spread and tumor-mesothelial crosstalk. Through this research, the University aims to develop medical solutions for the battlefield by investigating approaches to prevent cancer metastasis. The Military...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
This $520,259 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research at Carnegie Mellon University to develop a liquid biopsy-based approach for predicting pathological complete response in breast cancer patients. The project aims to leverage extracellular vesicles and advanced sequencing techniques to enable ultrasensitive detection of breast cancer-specific genetic mutations. As a...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Department of the Army Medical Command awarded a $1,520,818 Project Grant to Southern Research Institute under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2022 to June 30, 2025 to develop rank signaling inhibitors for treating breast cancer bone metastasis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...